Real-life data show feasibility of imatinib discontinuation in CML
Italian research shows that long-term imatinib discontinuation is feasible outside of a clinical trial setting for patients with chronic myeloid leukaemia who achieve stable undetectable molecular disease with front-line treatment.
Source: MedWire News - Category: Consumer Health News Tags: Oncology Source Type: news
More News: Cancer & Oncology | Chronic Leukemia | Chronic Myeloid Leukaemia | Clinical Trials | Gleevec | Health | Leukemia